Developer docs
API playgroundTry for free, no card

Search company profiles

AVECRIS

Full company profile

uuid00038tk

Namestring
AVECRIS
Legal namestring
Avecris
Websiteurl
avecris.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

AVECRIS is a Singapore-based, privately-held biotechnology company founded in 2017 that develops SPRING DNA™, a non-viral gene delivery platform technology originally invented by researchers at the National University of Singapore. The platform uses a rationally designed universal DNA construct with unique spring-like loop ends that enable exonuclease resistance, sustained expression, cell-type specific targeting via an on/off switch, redosability, immune-quiet behavior, non-integrating delivery, and accommodation of gene cargo of any size. AVECRIS positions SPRING DNA as a programmable alternative to viral vectors and RNA-based modalities (including mRNA, circular RNA, and self-amplifying RNA) for gene therapy, genetic vaccination, gene editing, and diagnostics across multiple therapeutic areas including genetic diseases, metabolic diseases, hematology, oncology, women's health, immunology, gastroenterology, ophthalmology, and dermatology.

The company's business model combines two revenue streams: direct product sales of SPRING DNA vectors for research and evaluation use (a 1 mg SPRING DNA research SKU is sold at $25,000 through an e-commerce storefront), and technology licensing and co-development arrangements with pharmaceutical, biotechnology, and government partners. The go-to-market motion is enterprise-led, anchored by strategic partnerships such as the inaugural Cystic Fibrosis Foundation Golden Ticket Award (July 2022) and BARDA's inaugural accelerator cohort and Health Security Industry Day spotlight (2022). The platform is supported by a comprehensive IP portfolio and a leadership team comprising CEO Pablo Cagnoni, CSO Volker Patzel, Co-founder and Managing Director Dennis Mak, Director of R&D Sushmita Poddar, and additional co-founders, directors, and scientific advisors with deep domain expertise in non-viral gene delivery and bioprocess manufacturing.

Short descriptiontext

AVECRIS is a Singapore-based biotech developing SPRING DNA™, a rationally designed non-viral gene delivery platform offering sustained, redosable, cell-type specific expression for gene therapy and genetic medicines. It serves pharmaceutical partners, research institutions, and government agencies via licensing, co-development, and direct research product sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
non-viral gene delivery, DNA vector platform, genetic medicines, gene therapy technology, biopharmaceutical licensing
Industry1 code
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Gene Therapy Platform Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1SPRING DNA Product Sales
TypeOne Time License
Description

Direct sales of SPRING DNA vectors for research and evaluation purposes. The company sells SPRING DNA vectors encoding reporter genes and promoters for laboratory use, with products like 1 mg SPRING DNA available at $25,000 per unit.

avecris.com
2Technology Licensing and Co-development
TypeLicensing Royalties
Description

Licensing of SPRING DNA platform technology to pharmaceutical and biotechnology partners for therapeutic development across multiple disease areas. Partnerships with organizations like BARDA and Cystic Fibrosis Foundation suggest government and foundation funding for co-development.

avecris.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
11 mg SPRING DNA for Evaluation Use
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$25,000.00 per 1 mg unit. SPRING DNA vector encoding reporter gene and promoter for evaluation use.

avecris.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1SPRING DNA
Description

A proprietary, minimalistic gene construct platform technology for non-viral DNA delivery with features including sustained expression, precise cell-type specific targeting, redosability, immune quiet properties, non-integrating mechanism, and ability to carry genes of any size.

avecris.com
+1 more record
Core offering1 text field

AVECRIS develops and commercializes SPRING DNA™, a proprietary non-viral gene delivery platform technology invented at the National University of Singapore. The platform enables sustained, precise, cell-type specific gene expression through a unique spring-like loop structure, with applications in gene therapy, genetic vaccination, gene editing, and diagnostics across multiple therapeutic areas. The company sells SPRING DNA vectors directly for research/evaluation use and licenses the platform to biopharmaceutical partners for therapeutic development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Single-day production and purification capability
+1 more record
Product overview1 text field

AVECRIS operates as a SPRING DNA™ platform company developing a new class of programmable genetic medicines. The core offering is the SPRING DNA™ technology platform, which enables non-viral DNA delivery with sustained, precise, cell-type specific gene expression. The platform is complemented by SPRING DNA research products (such as 1 mg SPRING DNA vectors) sold for evaluation use. The company is developing medicines across multiple therapeutic areas including genetic diseases, metabolic diseases, hematology, oncology, women's health, immunology, gastroenterology, ophthalmology, and dermatology, targeting applications in gene therapy, genetic vaccination, gene editing, and diagnostics.

Product and service2 records
1SPRING DNA Platform
CategoryGene Therapy Platform Technology
Description

A proprietary, programmable non-viral gene delivery platform technology that enables sustained, precise, cell-type specific gene expression. Licensed to biopharmaceutical companies for developing genetic medicines across multiple therapeutic areas including genetic diseases, oncology, rare diseases, metabolic diseases, hematology, immunology, ophthalmology, and dermatology.

21 mg SPRING DNA Research Vector
CategoryResearch Reagents
Description

SPRING DNA vector encoding reporter gene and promoter sold in 1 mg quantities at $25,000 per unit for evaluation and laboratory research use by research institutions and biopharmaceutical companies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1U.S. Department of Health and Human Services / BARDA
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

BARDA selected AVECRIS to spotlight at the 2022 BARDA Health Security Industry Day, recognizing the company's innovative biotechnology with applications in health security and pandemic preparedness. BARDA also selected AVECRIS for its inaugural accelerator cohort to develop innovative biomanufacturing capabilities.

avecris.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-21
Description

The Cystic Fibrosis Foundation awarded AVECRIS with the first ever Golden Ticket Award specifically designed to advance novel non-viral platform technology. This award recognizes innovative approaches to treating cystic fibrosis through genetic medicine.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based developer of doggybone DNA (dbDNA), a minimal, synthetic, closed-ended DNA vector for gene therapy and cell therapy. Closest direct competitor to SPRING DNA, also competing on exonuclease resistance, scalability, and elimination of bacterial backbone sequences.

TypeDirect peer
Description

US-based non-viral gene therapy company developing DNA-based therapeutics delivered via lipid nanoparticles, targeting genetic diseases. Shares the non-viral DNA delivery approach and redosability positioning that SPRING DNA emphasizes.

TypeDirect peer
Description

Belgium-based developer of DNA and mRNA production technologies with a focus on cost-efficient, scalable, enzymatic manufacturing. Highly comparable to SPRING DNA's enzymatic, single-day manufacturing thesis.

TypeEmerging player
Description

US-based Flagship Pioneering company developing 'gene writing' — a programmable approach to DNA-based therapeutics. Competes conceptually in the non-viral DNA space with SPRING DNA, targeting similar genetic-disease indications.

TypeEmerging player
Description

US-based developer of self-amplifying and programmable mRNA therapeutics with cell-type specific expression. Direct conceptual competitor to SPRING DNA's 'precise expression' positioning for next-generation genetic medicines.

TypeBroad incumbent
Description

US-based (now part of Danaher) manufacturer of plasmid DNA, mRNA, and proteins used across gene therapy and cell therapy pipelines. Comparable as a supplier/competitor in DNA-based therapeutic manufacturing for the same customer base as AVECRIS.

TypeBroad incumbent
Description

US-based (now part of Maravai LifeSciences) CDMO for mRNA, plasmid DNA, oligonucleotides, and nucleotides. Comparable as a nucleic-acid manufacturing competitor serving overlapping gene therapy customers.

TypeBroad incumbent
Description

mRNA platform incumbent with broad therapeutic and vaccine pipeline. Competes with SPRING DNA on the non-viral delivery frontier and explicitly on positioning that aims to displace traditional viral vectors.

TypeBroad incumbent
Description

mRNA and gene therapy incumbent spanning infectious disease vaccines and oncology. Competes for the same partner pharma customers and therapeutic indications as SPRING DNA in the broader non-viral genetic-medicine space.

TypeEmerging player
Description

US-based in vivo gene-editing company using lipid nanoparticle delivery of base-editing payloads. Comparable as a non-viral, in vivo genetic-medicine developer pursuing similar cardiology and rare-disease opportunities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AVECRIS

Gene Therapy Platform Technologyavecris.com

AVECRIS is a Singapore-based biotech developing SPRING DNA™, a rationally designed non-viral gene delivery platform offering sustained, redosable, cell-type specific expression for gene therapy and genetic medicines. It serves pharmaceutical partners, research institutions, and government agencies via licensing, co-development, and direct research product sales.

What AVECRIS does

AVECRIS is a Singapore-based, privately-held biotechnology company founded in 2017 that develops SPRING DNA™, a non-viral gene delivery platform technology originally invented by researchers at the National University of Singapore. The platform uses a rationally designed universal DNA construct with unique spring-like loop ends that enable exonuclease resistance, sustained expression, cell-type specific targeting via an on/off switch, redosability, immune-quiet behavior, non-integrating delivery, and accommodation of gene cargo of any size. AVECRIS positions SPRING DNA as a programmable alternative to viral vectors and RNA-based modalities (including mRNA, circular RNA, and self-amplifying RNA) for gene therapy, genetic vaccination, gene editing, and diagnostics across multiple therapeutic areas including genetic diseases, metabolic diseases, hematology, oncology, women's health, immunology, gastroenterology, ophthalmology, and dermatology.

The company's business model combines two revenue streams: direct product sales of SPRING DNA vectors for research and evaluation use (a 1 mg SPRING DNA research SKU is sold at $25,000 through an e-commerce storefront), and technology licensing and co-development arrangements with pharmaceutical, biotechnology, and government partners. The go-to-market motion is enterprise-led, anchored by strategic partnerships such as the inaugural Cystic Fibrosis Foundation Golden Ticket Award (July 2022) and BARDA's inaugural accelerator cohort and Health Security Industry Day spotlight (2022). The platform is supported by a comprehensive IP portfolio and a leadership team comprising CEO Pablo Cagnoni, CSO Volker Patzel, Co-founder and Managing Director Dennis Mak, Director of R&D Sushmita Poddar, and additional co-founders, directors, and scientific advisors with deep domain expertise in non-viral gene delivery and bioprocess manufacturing.

AVECRIS firmographics

Firmographics
Name
AVECRIS
Legal name
Avecris
Website
https://avecris.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
AVECRIS is a Singapore-based biotech developing SPRING DNA™, a rationally designed non-viral gene delivery platform offering sustained, redosable, cell-type specific expression for gene therapy and genetic medicines. It serves pharmaceutical partners, research institutions, and government agencies via licensing, co-development, and direct research product sales.
Ownership category
akta.pro rank

AVECRIS industry classification

Industry
Product category
Gene Therapy Platform Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Non-viral gene delivery
  • DNA vector platform
  • Genetic medicines
  • Gene therapy technology
  • Biopharmaceutical licensing

Where AVECRIS is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Markets served

AVECRIS business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. SPRING DNA Product Sales: Direct sales of SPRING DNA vectors for research and evaluation purposes. The company sells SPRING DNA vectors encoding reporter genes and promoters for laboratory use, with products like 1 mg SPRING DNA available at $25,000 per unit.
  2. Technology Licensing and Co-development: Licensing of SPRING DNA platform technology to pharmaceutical and biotechnology partners for therapeutic development across multiple disease areas. Partnerships with organizations like BARDA and Cystic Fibrosis Foundation suggest government and foundation funding for co-development.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-go1 mg SPRING DNA for Evaluation Use

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

AVECRIS product offering

Product offering

Core offering

AVECRIS develops and commercializes SPRING DNA™, a proprietary non-viral gene delivery platform technology invented at the National University of Singapore. The platform enables sustained, precise, cell-type specific gene expression through a unique spring-like loop structure, with applications in gene therapy, genetic vaccination, gene editing, and diagnostics across multiple therapeutic areas. The company sells SPRING DNA vectors directly for research/evaluation use and licenses the platform to biopharmaceutical partners for therapeutic development.

Product overview

AVECRIS operates as a SPRING DNA™ platform company developing a new class of programmable genetic medicines. The core offering is the SPRING DNA™ technology platform, which enables non-viral DNA delivery with sustained, precise, cell-type specific gene expression. The platform is complemented by SPRING DNA research products (such as 1 mg SPRING DNA vectors) sold for evaluation use. The company is developing medicines across multiple therapeutic areas including genetic diseases, metabolic diseases, hematology, oncology, women's health, immunology, gastroenterology, ophthalmology, and dermatology, targeting applications in gene therapy, genetic vaccination, gene editing, and diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • SPRING DNA: A proprietary, minimalistic gene construct platform technology for non-viral DNA delivery with features including sustained expression, precise cell-type specific targeting, redosability, immune quiet properties, non-integrating mechanism, and ability to carry genes of any size.
  • SPRING Science

Products and services

  • SPRING DNA Platform A proprietary, programmable non-viral gene delivery platform technology that enables sustained, precise, cell-type specific gene expression. Licensed to biopharmaceutical companies for developing genetic medicines across multiple therapeutic areas including genetic diseases, oncology, rare diseases, metabolic diseases, hematology, immunology, ophthalmology, and dermatology.
  • 1 mg SPRING DNA Research Vector SPRING DNA vector encoding reporter gene and promoter sold in 1 mg quantities at $25,000 per unit for evaluation and laboratory research use by research institutions and biopharmaceutical companies.

Quantifiable outcome

  • Single-day production and purification capability
  • +1 more outcomes

Companies that use AVECRIS

Customer profile

Segments3 records

Ideal customer profiles2 records

AVECRIS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AVECRIS partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • U.S. Department of Health and Human Services / BARDAcoreStrategic or Co-development Partner · 1 November 2022BARDA selected AVECRIS to spotlight at the 2022 BARDA Health Security Industry Day, recognizing the company's innovative biotechnology with applications in health security and pandemic preparedness. BARDA also selected AVECRIS for its inaugural accelerator cohort to develop innovative biomanufacturing capabilities.
  • Cystic Fibrosis FoundationcoreStrategic or Co-development Partner · 21 July 2022The Cystic Fibrosis Foundation awarded AVECRIS with the first ever Golden Ticket Award specifically designed to advance novel non-viral platform technology. This award recognizes innovative approaches to treating cystic fibrosis through genetic medicine.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

AVECRIS competitors and assessment

Company assessment

Direct peers

  • Touchlight Genetics: UK-based developer of doggybone DNA (dbDNA), a minimal, synthetic, closed-ended DNA vector for gene therapy and cell therapy. Closest direct competitor to SPRING DNA, also competing on exonuclease resistance, scalability, and elimination of bacterial backbone sequences.
  • Generation Bio: US-based non-viral gene therapy company developing DNA-based therapeutics delivered via lipid nanoparticles, targeting genetic diseases. Shares the non-viral DNA delivery approach and redosability positioning that SPRING DNA emphasizes.
  • Quantoom Biosciences: Belgium-based developer of DNA and mRNA production technologies with a focus on cost-efficient, scalable, enzymatic manufacturing. Highly comparable to SPRING DNA's enzymatic, single-day manufacturing thesis.

Emerging players

  • Tessera Therapeutics: US-based Flagship Pioneering company developing 'gene writing' — a programmable approach to DNA-based therapeutics. Competes conceptually in the non-viral DNA space with SPRING DNA, targeting similar genetic-disease indications.
  • Strand Therapeutics: US-based developer of self-amplifying and programmable mRNA therapeutics with cell-type specific expression. Direct conceptual competitor to SPRING DNA's 'precise expression' positioning for next-generation genetic medicines.
  • Verve Therapeutics: US-based in vivo gene-editing company using lipid nanoparticle delivery of base-editing payloads. Comparable as a non-viral, in vivo genetic-medicine developer pursuing similar cardiology and rare-disease opportunities.

Broad incumbents

  • Aldevron: US-based (now part of Danaher) manufacturer of plasmid DNA, mRNA, and proteins used across gene therapy and cell therapy pipelines. Comparable as a supplier/competitor in DNA-based therapeutic manufacturing for the same customer base as AVECRIS.
  • TriLink BioTechnologies: US-based (now part of Maravai LifeSciences) CDMO for mRNA, plasmid DNA, oligonucleotides, and nucleotides. Comparable as a nucleic-acid manufacturing competitor serving overlapping gene therapy customers.
  • Moderna: mRNA platform incumbent with broad therapeutic and vaccine pipeline. Competes with SPRING DNA on the non-viral delivery frontier and explicitly on positioning that aims to displace traditional viral vectors.
  • BioNTech: mRNA and gene therapy incumbent spanning infectious disease vaccines and oncology. Competes for the same partner pharma customers and therapeutic indications as SPRING DNA in the broader non-viral genetic-medicine space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

AVECRIS social profiles

Digital presence

AVECRIS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AVECRIS leadership team

Management profile

Number of profiles

Profiles8 records

AVECRIS funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AVECRIS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AVECRIS

What does AVECRIS do?

AVECRIS develops and commercializes SPRING DNA™, a proprietary non-viral gene delivery platform technology invented at the National University of Singapore. The platform enables sustained, precise, cell-type specific gene expression through a unique spring-like loop structure, with applications in gene therapy, genetic vaccination, gene editing, and diagnostics across multiple therapeutic areas. The company sells SPRING DNA vectors directly for research/evaluation use and licenses the platform to biopharmaceutical partners for therapeutic development.

Is AVECRIS a public or private company?

AVECRIS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was AVECRIS founded?

AVECRIS was founded in 2022. It employs 1 to 10 people.

Where is AVECRIS based?

AVECRIS is headquartered in Singapore, Singapore, in the Asia region.

How does AVECRIS make money?

Two revenue lines are on record. SPRING DNA Product Sales are the primary driver. The others are technology Licensing and Co-development.

Who are AVECRIS's main competitors?

Direct peers on record are Touchlight Genetics, Generation Bio and Quantoom Biosciences. Emerging players are Tessera Therapeutics, Strand Therapeutics and Verve Therapeutics. Broad incumbents are Aldevron, TriLink BioTechnologies, Moderna and BioNTech.

Does AVECRIS have an API?

No public API is recorded for AVECRIS.

What industry is AVECRIS in?

AVECRIS's product category is Gene Therapy Platform Technology. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales